Creating new antibodies to improve AIDS treatment
Development of Broadly Neutralizing Nanobodies for Advancing AIDS Therapy
This study is working on creating tiny, powerful antibodies that can better fight HIV/AIDS by targeting different parts of the virus, making treatment easier and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11009418 on NIH RePORTER |
What this research studies
This research focuses on developing broadly neutralizing nanobodies to enhance the treatment of HIV/AIDS. By utilizing advanced techniques, the team aims to engineer smaller antibodies that can effectively target multiple sites on the HIV virus, potentially overcoming challenges faced by traditional therapies. The study will involve identifying versatile nanobodies through innovative screening methods and evaluating their effectiveness against various HIV strains. This approach seeks to simplify treatment protocols while improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV/AIDS who are seeking improved treatment options.
Not a fit: Patients who are not infected with HIV or those who have already achieved viral suppression with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and easier-to-administer treatments for HIV/AIDS patients.
How similar studies have performed: Previous research has shown promise in using engineered antibodies for HIV treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Xu, Jianliang — Georgia State University
- Study coordinator: Xu, Jianliang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.